Format

Send to

Choose Destination
Cancer Epidemiol. 2016 Apr;41:152-8. doi: 10.1016/j.canep.2015.12.011. Epub 2016 Feb 16.

Surveillance of effects of HPV vaccination in Belgium.

Author information

1
Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, J. Wytsmanstreet 14, B1050 Brussels, Belgium. Electronic address: marc.arbyn@wiv-isp.be.
2
International Centre for Reproductive Health (ICRH), Ghent University, Ghent, Belgium; Algemeen Medisch Labo, Sonic Healtcare, Antwerp, Belgium; AMBIOR, Laboratory for Cell Biology & Histology, University of Antwerp, Antwerp, Belgium.
3
Algemeen Medisch Labo, Sonic Healtcare, Antwerp, Belgium; AMBIOR, Laboratory for Cell Biology & Histology, University of Antwerp, Antwerp, Belgium.
4
Algemeen Medisch Labo, Sonic Healtcare, Antwerp, Belgium.
5
N. Goormachtigh Institute for Pathology, Ghent University, Ghent, Belgium.
6
Department of Gynaecology & Oncology, UZ Brussel, Free University of Brussels, Brussels, Belgium.
7
Department of Pathology, VUB, Brussels, Belgium.
8
Department of Pathology, UZ Leuven, Leuven, Belgium.
9
Department of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium.
10
Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium.
11
Department of Pathology, ULg, Liège, Belgium.
12
Institut de Pathologie et de Génétique, Charlerloi, Belgium.
13
Centrum voor Medische Analyse, Herentals, Belgium.
14
Pathological Anatomy, AZ Groeninge, Kortrijk, Belgium.
15
Pathology Mariaziekenhuis Noord Limburg, Overpelt, Belgium.
16
Vaccine & Infectious Disease Institute (VAXINFECTIO), Antwerp University, Antwerp, Belgium.
17
International Centre for Reproductive Health (ICRH), Ghent University, Ghent, Belgium; Reproductive Health and Research, World Health Organization, Geneva, Switzerland; Department of Gynaecology and Obstetrics, Ghent University, Ghent, Belgium.
18
Department of Gynaecology and Obstetrics, Ghent University, Ghent, Belgium.

Abstract

BACKGROUND:

Early effects of HPV (human papillomavirus) vaccination are reflected by changes observable in young women attending cervical cancer screening.

SUBJECT AND METHODS:

The SEHIB study included HPV geno-typing of ∼6000 continuous and 650 pathological cervical cell specimen as well as biopsies, collected from women in Belgium in 2010-2014. Data were linked to vaccination status.

RESULTS:

HPV vaccination offered protection among women aged <30years against infection with HPV16 (vaccine effectiveness [VE]=67%, 95% CI: 48-79%), HPV18 (VE=93%, 95% CI: 52-99%), and high-risk HPV (VE=16%, 95% CI: 2-29%). Vaccination protected also against cytological lesions. Vaccination protected against histologically confirmed lesions: significantly lower absolute risks of CIN1+ (risk difference [RD]=-1.6%, 95% CI: -2.6% to -0.7%) and CIN3+ associated with HPV16/18 (RD=-0.3%, 95% CI -0.6% to -0.1%). Vaccine effectiveness decreased with age. Protection against HPV16 and 18 infection was significant in all age groups, however no protection was observed against cytological lesions associated with these types in age-group 25-29.

CONCLUSION:

The SEHIB study demonstrates the effectiveness of HPV vaccination in Belgian young women in particular in age group 18-19. Declining effectiveness with increasing age may be explained by higher tendency of women already exposed to infection to get the vaccine.

KEYWORDS:

Cervical cancer; HPV; HPV vaccination; Human papillomavirus; Screening; Surveillance

PMID:
26895623
DOI:
10.1016/j.canep.2015.12.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center